International AIDS Conference
Antiretroviral therapy decreases 25-OH vitamin D levels in HIV/HBV coinfected patients
Patients coinfected with hepatitis B and HIV had lower serum levels of 25-hydroxyvitamin D and were more likely to be considered vitamin D deficient after initiating antiretroviral therapy in a study presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Liver stiffness more predictive of decompensation than biopsy results in HIV/HCV coinfection
Liver stiffness measurement is similarly predictive of overall mortality and more predictive of decompensation than liver biopsy results among patients with HIV/HCV coinfection, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Poorer antiretroviral response among HIV patients with HBV, HCV coinfection
Patients with HIV coinfected with hepatitis B or hepatitis C virus experienced poorer outcomes from antiretroviral therapy compared with monoinfected patients in a study presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Interferon-based therapy similarly effective with normal, elevated ALT in HCV/HIV coinfected patients
Treatment with pegylated interferon alfa-2a and ribavirin yielded similar response rates in patients with HIV and HCV coinfection with elevated and persistently normal ALT in a study presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Poor treatment outcomes common among children with HIV/HCV coinfection
European children with HIV/HCV coinfection often have poor outcomes from HCV therapy, according to results presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
SPRING-2: Dolutegravir with NRTI backbone potential HIV treatment
Dolutegravir was noninferior to raltegravir when combined with a nucleoside reverse transcriptase inhibitor backbone in previously untreated patients with HIV, according to the results of a trial presented at the 2013 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Social factors increased suicide risk in HIV patients
Factors such as having low social support and facing stigma significantly increased risk for suicide in HIV-infected adolescents and adults, according to study results presented at the 2013 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Social factors increased suicide risk in HIV patients
Factors such as having low social support and facing stigma significantly increased risk for suicide in HIV-infected adolescents and adults, according to study results presented at the 2013 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Thrombospondin new biomarker for HIV
The protein thrombospondin, encoded by the THBS1 gene, is a new biomarker for plasma viremia in patients with progressive and non-progressive HIV, according to the results of a study presented at the 2013 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
High SVR rates with DAA regimen among chronic HCV patients
Sustained virologic response to a regimen of three antivirals and ribavirin was highly prevalent with or without a ribavirin dose reduction among patients with chronic HCV in a study presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.